Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia
- Correspondence to: Y Ikuno Department of Ophthalmology, Osaka University Medical School, 2-2 Yamadaoka, E7, Suita, Osaka 565-0871, Japan;
- Accepted 31 July 2006
- Published Online First 16 August 2006
Aim: To assess the efficacy and safety of an intravitreal injection of bevacizumab (Avastin®) for myopic choroidal neovascularisation (mCNV).
Methods: Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months.
Results: The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed.
Conclusion: Intravitreal injection of bevacizumab seems to be an effective and safe treatment for mCNV.
- AMD, age-related macular degeneration
- BCVA, best-corrected visual acuity
- CNV, choroidal neovascularisation
- mCNV, myopic choroidal neovascularisation
- OCT, optical coherence tomography
- PDT, photodynamic therapy
- VEGF, vascular endothelial growth factor
Published Online First 16 August 2006
This work was Supported by Health Sciences Research Grant from the Ministry of Health, Labor and Welfare, Japan. We have no proprietary interest in any aspect of this report.
Competing interests: None declared.